about
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the fieldTargeting the SH2-Kinase Interface in Bcr-Abl Inhibits LeukemogenesisA target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLStat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformationOverexpression of primary microRNA 221/222 in acute myeloid leukemia.Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinRac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816HPhenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells.Standards and impact of hematopathology in myelodysplastic syndromes (MDS).Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils.Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasmIdentification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
P50
Q27003331-FBC7ED0A-92CD-4045-AC4A-AC9A61A0A94DQ27675049-1C50F9C9-A184-42B0-874A-E1DA510295C4Q28534337-6232C82C-C3E5-4541-9ACE-A1FF520B57B5Q34124973-245105B6-AD52-4263-8FCD-49376035B395Q34877897-BC7C94A4-B93D-4532-BEC8-BED3A1720180Q35153623-244F9A02-B7CD-4910-BD18-64DEA33AB10AQ35169575-4471B377-3E6E-4B37-927A-ED0B079AF936Q35717808-90D669CC-CDAF-4EA8-8987-93033EEED99EQ35986641-A85BA118-633C-4371-B2A6-CB529D428595Q36755221-229B10DB-7925-40B3-A6EA-8FAB7E01927FQ36851400-BB52535C-922E-4922-8EE4-117E1851A3FBQ36926120-4426C700-FEA7-4965-934F-8BABE051DD10Q36977300-57B5EE4E-F8C2-4A8E-8543-2418196391C3Q37038076-A8D7D90D-3F7F-4FEB-B889-089CAA6E16ACQ37462729-D853C1D3-E917-4204-BB70-74AFC850851FQ37611613-433EAD39-64D2-4E9F-8F5E-B19D1140CE16Q37812862-864A0A18-267B-49E2-805E-637143475704Q37840934-C127E06E-507E-412A-AE2A-B54E66D54A2AQ38193659-D685F532-964B-4F2F-8F92-6EDDBB60B24AQ38265115-6D5047B8-0870-4C40-B8A0-F4965027117EQ39010730-9A8EA856-111D-45F0-A960-F78013B96773Q39093823-56CE8F78-4BC1-4BE2-954D-DC46598AF5F6Q39276326-D27E0771-7AB9-4433-B3F8-B0605DAC2673Q39289359-3233CEC7-7A73-4FDB-ADFA-9CEF33C544C1Q39294830-3D453E5D-C12C-4BB2-8D79-8D6C56081D44Q39375748-42C5679F-4283-4D27-A162-A22A71CAC6B0Q39448460-0B42C18C-AAE0-4DE9-B09B-293FC7986EFEQ39523051-BD14990D-6FD3-46AA-9950-07DB4305957BQ39606792-1ADFA851-8FBF-4198-8200-759D92C32AD0Q39615506-AC9BB109-9CF3-41B0-AAFB-3E5AEF646667Q39741527-9E1FACBE-A0BA-467A-A033-2FBD6F79277FQ41964099-4CBDD073-B832-487A-A467-FE1F0EAD12DBQ42153537-2E72430B-B98D-4EAD-BEF2-C2BC5DB54BCBQ42217439-BCB7BEB0-3D8E-4C6F-8FAF-03B583DBEFDDQ43256442-A0451B86-55F9-4C57-AE47-D37805A9722E
P50
name
Sabine Cerny-Reiterer
@ast
Sabine Cerny-Reiterer
@en
Sabine Cerny-Reiterer
@es
Sabine Cerny-Reiterer
@fr
Sabine Cerny-Reiterer
@nl
type
label
Sabine Cerny-Reiterer
@ast
Sabine Cerny-Reiterer
@en
Sabine Cerny-Reiterer
@es
Sabine Cerny-Reiterer
@fr
Sabine Cerny-Reiterer
@nl
prefLabel
Sabine Cerny-Reiterer
@ast
Sabine Cerny-Reiterer
@en
Sabine Cerny-Reiterer
@es
Sabine Cerny-Reiterer
@fr
Sabine Cerny-Reiterer
@nl